ALKS
Alkermes plc.
$42.80
-1.34%
$7.2B
No data for this timeframe.
Vol
Market Cap$7.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (83%)
Insider Activity0B / 3S
Insider Net $-$1.1M
SEC Reports10
Recent Activity
Jun 4, 2026
SEC
Three Alkermes insiders, including the EVP R&D/CMO and VP Finance, sold a total of ~$1.15M in open-market sales over a 7
CLUSTER — Impact 3/10
Jun 4, 2026
Insider
Gaffin David Joseph sold 2,034 shares
EVP, CLO, Alkermes, Inc. @ $43.05 ($87.6K)
Jun 4, 2026
short_volume
Short Volume: ALKS — 69.9% short (0.6M / 0.8M)
Short: 588,030 | Exempt: 0 | TRF Vol: 841,079 | Short Ratio: 69.9% | Off-exchange volume (dark pool
Jun 1, 2026
SEC
Two Alkermes insiders — the Chief Medical Officer and the Interim Principal Accounting Officer — sold a combined $1.06M
CLUSTER — Impact 2/10
Jun 1, 2026
Insider
Hopkinson Craig C. sold 9,000 shares
EVP R&D, Chief Medical Officer @ $41.67 ($375.0K)
Jun 1, 2026
Insider
Hopkinson Craig C. sold 5,000 shares
EVP R&D, Chief Medical Officer @ $0.00 ($0.00)
May 20, 2026
SEC
Alkermes filed an 8-K reporting results of its 2026 annual meeting, where shareholders approved an amendment to the 2018
8-K — Impact 3/10
Price Targets
$45.44
+6.2% upside
Buy
Current $42.80
Low $34.00
Median $45.00
High $59.00
16 analysts
$34.00
$59.00
Analyst Ratings
6Strong Buy
13Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| May 6, 2026 | UBS | MAINTAIN | Buy → Buy |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 6, 2026 | Needham | MAINTAIN | Buy → Buy |
| Apr 9, 2026 | B of A Securities | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next Q | $0.36 ▲ +1701.9% | $0.00 — $0.72 | -45% YoY | 4 |
| Current Q | $0.33 ▲ +557.5% | $-0.07 — $0.76 | -52% YoY | 4 |
| Next FY | $2.35 ▲ +236.4% | $1.01 — $4.75 | 64% YoY | 4 |
| Current FY | $1.43 ▲ +2288.2% | $0.24 — $2.78 | -32% YoY | 4 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Three Alkermes insiders, including the EVP R&D/CMO and VP Finance, sold a total of ~$1.15M in open-market sales over a 7
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
Two Alkermes insiders — the Chief Medical Officer and the Interim Principal Accounting Officer — sold a combined $1.06M
Jun 1, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Gaffin David | SELL | $87.6K |
| Jun 1, 2026 | Hopkinson Craig | SELL | $375.0K |
| Jun 1, 2026 | Hopkinson Craig | M | $0.00 |
| Jun 1, 2026 | Hopkinson Craig | M | $96.7K |
| May 29, 2026 | Parisi Samuel | M | $67.9K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
11 unique insiders with 3 transactions. Net insider value: -$1.1M ($0.00 bought, $1.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | SELL | 2,034 | $43.05 | $87.6K |
| Jun 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | SELL | 9,000 | $41.67 | $375.0K |
| Jun 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | 5,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | 5,000 | $19.34 | $96.7K |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | 3,392 | $20.03 | $67.9K |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | SELL | 16,217 | $42.36 | $687.0K |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | 3,392 | $0.00 | $0.00 |
| May 21, 2026 | GAYNOR RICHARD | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Cooke Shane | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Cooke Shane | Director | F | 3,207 | $36.95 | $118.5K |
| May 21, 2026 | Cooke Shane | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | GAYNOR RICHARD | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | GAYNOR RICHARD | Director | F | 1,475 | $36.95 | $54.5K |
| May 21, 2026 | LAURENCIN CATO T | Director | F | 1,475 | $36.95 | $54.5K |
| May 21, 2026 | LAURENCIN CATO T | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Lurker Nancy | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | LAURENCIN CATO T | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Lurker Nancy | Director | F | 1,475 | $36.95 | $54.5K |
| May 21, 2026 | Lurker Nancy | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | MCKEON BRIAN P | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | MCKEON BRIAN P | Director | F | 1,475 | $36.95 | $54.5K |
| May 21, 2026 | MCKEON BRIAN P | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | snyderman nancy lynn MD | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | snyderman nancy lynn MD | Director | F | 1,475 | $36.95 | $54.5K |
| May 21, 2026 | snyderman nancy lynn MD | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Wilson Frank Anders | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Wilson Frank Anders | Director | F | 1,475 | $36.95 | $54.5K |
| May 21, 2026 | Wilson Frank Anders | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Wright Christopher I | Director | M | 6,142 | $0.00 | $0.00 |
| May 21, 2026 | Wright Christopher I | Director | F | 1,475 | $36.95 | $54.5K |
| May 21, 2026 | Wright Christopher I | Director | M | 6,142 | $0.00 | $0.00 |
| May 20, 2026 | Cooke Shane | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | Cooke Shane | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | GAYNOR RICHARD | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | GAYNOR RICHARD | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | Cooke Shane | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | Cooke Shane | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | GAYNOR RICHARD | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | GAYNOR RICHARD | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | LAURENCIN CATO T | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | LAURENCIN CATO T | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | Lurker Nancy | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | Lurker Nancy | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | MCKEON BRIAN P | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | MCKEON BRIAN P | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | snyderman nancy lynn MD | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | snyderman nancy lynn MD | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | Wilson Frank Anders | Director | A | 11,538 | $0.00 | $0.00 |
| May 20, 2026 | Wilson Frank Anders | Director | A | 5,409 | $0.00 | $0.00 |
| May 20, 2026 | Wright Christopher I | Director | A | 11,538 | $0.00 | $0.00 |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 2 mixed, 7 neutral. Avg impact: 3.7/10.
NEUTRAL
CLUSTER
3/10
Three Alkermes insiders, including the EVP R&D/CMO and VP Finance, sold a total of ~$1.15M in open-m
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
Two Alkermes insiders — the Chief Medical Officer and the Interim Principal Accounting Officer — sol
Jun 1, 2026
NEUTRAL
8-K
3/10
Alkermes filed an 8-K reporting results of its 2026 annual meeting, where shareholders approved an a
May 20, 2026
NEUTRAL
DEFA14A
2/10
Alkermes filed a DEFA14A on May 13, 2026, sending an email to employees encouraging them to vote the
May 13, 2026
BULLISH
8-K
7/10
Alkermes announced positive topline results from the REVITALYZ Phase 3 study of LUMRYZ in idiopathic
May 12, 2026
MIXED
8-K
5/10
Alkermes reported Q1 2026 revenue of $392.9M, up 28% YoY, driven by the Avadel acquisition adding LU
May 5, 2026
NEUTRAL
CLUSTER
2/10
Two Alkermes insiders — the EVP/CLO and EVP R&D/Chief Medical Officer — sold a combined $368K in ope
May 5, 2026
NEUTRAL
CLUSTER
3/10
Three executives at Alkermes sold shares in the past week, including two open-market sales by EVPs G
Mar 5, 2026
NEUTRAL
8-K
4/10
Alkermes plc announced the retirement of CEO and Chairman Richard F. Pops, effective July 31, 2026,
Feb 25, 2026
MIXED
8-K
6/10
Alkermes reported 2025 total revenues of $1.48 billion and diluted GAAP EPS of $1.43, with a 9% year
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 23 analysts: 6 strong buy, 13 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$45.44 mean target
+6.2% upside
Buy (1.53)
$34.00 Low
$59.00 High
| Metric | Value |
|---|---|
| Current Price | $42.80 |
| Target Low | $34.00 |
| Target Mean | $45.44 |
| Target Median | $45.00 |
| Target High | $59.00 |
| # Analysts | 16 |
| Recommendation | Buy (1.53) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next Q 2026-09-30 |
$0.36 | $0.00 | $0.72 | -44.6% | +1701.9% | — | $0.5B | 19.9% | 4 |
| Current Q 2026-06-30 |
$0.33 | $-0.07 | $0.76 | -51.6% | +557.5% | — | $0.5B | 17.2% | 4 |
| Next FY 2027-12-31 |
$2.35 | $1.01 | $4.75 | 64.3% | +236.4% | 1↑ 0↓ | $1.9B | 4.2% | 4 |
| Current FY 2026-12-31 |
$1.43 | $0.24 | $2.78 | -31.7% | +2288.2% | — | $1.8B | 22.7% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.329 | |
| 7d ago | $0.050 | +0.279 |
| 30d ago | $0.050 | +0.279 |
| 60d ago | $0.325 | +0.004 |
| 90d ago | $0.572 | -0.243 |
16 analyst firms have rated this stock: 4 upgrades, 0 downgrades, 7 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Mar 24, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Feb 20, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Nov 17, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Nov 13, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Nov 13, 2025 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Nov 12, 2025 | Truist Securities | REITERATE | Buy | Buy |
| Nov 11, 2025 | Truist Securities | INITIATE | — | Buy |
| Oct 29, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Oct 29, 2025 | Needham | MAINTAIN | Buy | Buy |
| Oct 27, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Oct 23, 2025 | Piper Sandler | REITERATE | Overweight | Overweight |
| Oct 23, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Sep 26, 2025 | RBC Capital | UPGRADE | Sector Perform | Outperform |
| Sep 9, 2025 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Sep 9, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Sep 3, 2025 | Wells Fargo | INITIATE | — | Overweight |
| Jul 30, 2025 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Jul 29, 2025 | Needham | REITERATE | Buy | Buy |
| Jul 21, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Jul 21, 2025 | Needham | REITERATE | Buy | Buy |
| Jul 15, 2025 | Goldman Sachs | INITIATE | — | Buy |
| Jun 17, 2025 | UBS | UPGRADE | Neutral | Buy |
| May 28, 2025 | Needham | INITIATE | — | Buy |
| May 2, 2025 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| May 2, 2025 | Baird | MAINTAIN | Outperform | Outperform |
| Apr 28, 2025 | UBS | MAINTAIN | Neutral | Neutral |
| Mar 27, 2025 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Mar 13, 2025 | RBC Capital | INITIATE | — | Sector Perform |
| Mar 4, 2025 | UBS | UPGRADE | Sell | Neutral |
| Feb 14, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Feb 13, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Feb 11, 2025 | Deutsche Bank | INITIATE | — | Buy |
| Nov 13, 2024 | Mizuho | MAINTAIN | Outperform | Outperform |
| Nov 5, 2024 | Stifel | UPGRADE | Hold | Buy |
| Oct 25, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Oct 25, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Oct 25, 2024 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Oct 25, 2024 | Piper Sandler | REITERATE | Overweight | Overweight |
| Oct 25, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Oct 14, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Oct 10, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 16, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 13 | 4 | 0 | 0 | 83% | |
| May 1, 2026 | 6 | 14 | 4 | 0 | 0 | 83% | |
| Apr 1, 2026 | 6 | 14 | 4 | 0 | 0 | 83% | |
| Mar 1, 2026 | 6 | 14 | 4 | 0 | 0 | 83% | |
| Feb 1, 2026 | 5 | 14 | 4 | 0 | 0 | 83% | |
| Jan 1, 2026 | 5 | 14 | 4 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
short_volume
Short Volume: ALKS — 69.9% short (0.6M / 0.8M)
Short: 588,030 | Exempt: 0 | TRF Vol: 841,079 | Short Ratio: 69.9% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: ALKS — 55.9% short (0.4M / 0.7M)
Short: 375,961 | Exempt: 0 | TRF Vol: 672,036 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: ALKS — 59.8% short (0.4M / 0.6M)
Short: 366,137 | Exempt: 231 | TRF Vol: 612,715 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: ALKS — 55.1% short (0.8M / 1.4M)
Short: 776,998 | Exempt: 0 | TRF Vol: 1,411,345 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: ALKS — 58.0% short (0.3M / 0.6M)
Short: 331,053 | Exempt: 0 | TRF Vol: 570,713 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: ALKS — 59.8% short (0.7M / 1.2M)
Short: 705,321 | Exempt: 59,752 | TRF Vol: 1,178,604 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
ALKS Q1 2026 Earnings Scheduled — 2026-05-05
May 5, 2026
short_volume
Short Volume: ALKS — 56.3% short (0.5M / 0.9M)
Short: 529,398 | Exempt: 0 | TRF Vol: 940,566 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_interest
FTD: ALKS — 182,241 shares ($6.2M) failed to deliver
Settlement: 20260505, Price: $34.17, FTD Value: $6,227,174.97, ALKERMES PLC ORDINARY SHS (IRE
May 4, 2026
short_volume
Short Volume: ALKS — 63.9% short (0.8M / 1.2M)
Short: 794,544 | Exempt: 0 | TRF Vol: 1,243,187 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
earnings_calendar
ALKS Q1 2026 Earnings Scheduled — 2026-04-29
Apr 29, 2026
short_volume
Short Volume: ALKS — 61.7% short (0.8M / 1.2M)
Short: 765,551 | Exempt: 3,586 | TRF Vol: 1,239,919 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: ALKS — 58.2% short (0.3M / 0.6M)
Short: 321,667 | Exempt: 0 | TRF Vol: 552,527 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_interest
FTD: ALKS — 69,054 shares ($2.4M) failed to deliver
Settlement: 20260420, Price: $34.53, FTD Value: $2,384,434.62, ALKERMES PLC ORDINARY SHS (IRE
Apr 16, 2026
short_volume
Short Volume: ALKS — 56.4% short (0.3M / 0.6M)
Short: 311,135 | Exempt: 0 | TRF Vol: 551,541 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)